Evidence map›Paper›PMID 39726887›Full record

ArticleJournal of biomedical physics & engineering2024

Photosensitizing Activity of Nanoparticles of Poly (2-amino phenol)/Gold for Intensified Doxorubicin Therapeutic Effect on Melanoma Cancer Cells under Synergism Effect of 808-nm Light.

Naghmeh Sattarahmady, Zahra Kayani, Hossein Heli, Parsa Faghani-Eskandarkolaei, Hanieh Haghighi

Abstract read
In one paragraph

Article in Journal of biomedical physics & engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Naghmeh SattarahmadyNanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra KayaniNanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hossein HeliNanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Parsa Faghani-EskandarkolaeiDepartment of Medical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Hanieh HaghighiNanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Photothermal therapy (PTT) is one of the effective and non-invasive strategies which hold great promise for improving the treatment of cancer cells. PTT is based on activating a photosensitizer by infrared light irradiation and producing heat and reactive species and apoptosis in the tumor area. Objective: The aim of this study was to investigate the effect of photothermal/chemotherapy on melanoma cancer cells using poly (2-amino phenol)/gold (P2AO/AuNPs) and doxorubicin (DOX). Material and Methods: In this experimental study, nanoparticles of P2AO/AuNPs were synthesized, and their mixture with DOX was applied as a photosensitizer for photothermal/chemotherapy of a C540 (B16-F10) melanoma cell line. Results: P2AO/AuNPs generated heat and cytotoxic responsive oxygen species (ROS) upon 808-nm light irradiation with simultaneous intensifying DOX therapeutic effect under domination of synergism effects between light irradiation, P2AO/AuNPs, and doxorubicin. Cell treatment with both P2AO/AuNPs and DOX resulted in a considerable increase in necroptotic cells to 61% with a significant decrease in the living cells (39%). Conclusion: P2AO/AuNPs provided a platform for light absorption and intensifying DOX therapeutic effect. This study approved the applicability of a new photothermal/chemotherapy by domination of synergistic effects attained by combination of laser light, P2AO, AuNPs, and DOX.

Indexed as

ApoptosisDoxorubicinMalignant MelanomaMetal NanoparticlesPhotoablationPhototherapy

Identifiers

PMID39726887
PMCPMC11668927

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.